Federal Official Gazette
As has become customary in recent weeks, the Nov 14, 2025 edition was not made available on the correct day. In any case, there are no updates on either Nov 14 or Nov 17.
ANS news
We cannot treat human life as a detail,” says ANS’s chief executive officer
The remarks were made during the seminar “Equilíbrio Possível: Saúde e Remédio de Alto Custo” (Possible Balance: Health and High-Cost Medicines), held in Brasília
Open public consultations
- CP 163. Its purpose is to receive input on the proposals to update the List of Health Procedures and Events (Rol), specifically on the preliminary recommendation against incorporation for the technologies covered by UAT No. 171 – Inclisiran, UAT No. 175 – Lebrikizumab and UAT No. 176 – Momelotinib. Deadline: Nov 5, 2025 to Nov 24, 2025
Scheduled public hearings
- Public Hearing No. 61, collection of input on the preliminary recommendation against incorporation for the following technologies:
(i) UAT 171 – Inclisiran for the treatment of primary hypercholesterolemia or mixed dyslipidemia;
(ii) UAT 175 – Lebrikizumab for the treatment of adult patients with severe atopic dermatitis who have failed, are intolerant to or have a contraindication to cyclosporine; and
(iii) UAT 176 – Momelotinib for the treatment of intermediate- and high-risk myelofibrosis.
Date: November 19, 2025, from 9 a.m. to 1 p.m.
Open public calls for input
There are no open public calls for input.
Open public calls
No updates.
Other news
– No updates.
Sources: Federal Official Gazette (DOU) and the ANS website. Press items link to the original article. This brief is for information only and does not constitute legal advice.